Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

NCT01505608 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Lack of Enrollment

Conditions

Neuroblastoma

Interventions

DRUG: TPI 287
DRUG: Temozolomide
DRUG: Irinotecan

Sponsor

Giselle Sholler

Collaborators

[object Object]